Kymera Therapeutics
KYMR | NASDAQ
$125.85
-$1.72 (-1.35%)
At close: Nov 16, 2026, 4:00 PM ET
$123.50
-$2.35 (-1.87%)
After-hours:
Nov 16, 2026, 7:59 PM ET
Kymera Therapeutics Company Profile
Company profile explainedCompany Profile
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Nello Mainolfi | Co-Founder, President, Chief Executive Officer & Director |
| Brian R. Adams | Chief Legal Officer & Corporate Secretary |
| Bruce N. Jacobs | Chief Financial Officer |
| Brian Albarran | SVP of Corporate Strategy |
| Jared A. Gollob | Advisor |
| Jeremy G. Chadwick | Advisor |
| Juliet Williams | Head of Research |
| Justine E. Koenigsberg | Vice President of Investor Relations |
| Neil Graham MBBS | Chief Development Officer |
| Noah Goodman | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 01, 2026 | 4 | Filing |
| Sep 08, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 04, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
Kymera Therapeutics
| Country | United States |
| IPO Date | Aug 21, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 273 |
| CEO | Nello Mainolfi |
Contact Details
500 North Beacon Street Watertown,
Massachusetts 02472 United States
Stock Details
| Ticker Symbol | KYMR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001815442 |
| CUSIP Number | 501575104 |
| ISIN Number | US5015751044 |
| SIC Code | 2836 |
Recent News
- 18 days ago / seekingalpha.comKymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
- 18 days ago / marketbeat.comKymera Therapeutics Q3 Earnings Call Highlights
- 19 days ago / globenewswire.comKymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
- 19 days ago / globenewswire.comKymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
- 25 days ago / globenewswire.comKymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
- 29 days ago / zacks.comCan KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
- 2 months ago / seekingalpha.comKymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / seekingalpha.comKymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- 2 months ago / zacks.comKymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
- 2 months ago / zacks.comCan KT-621 Mark a Turning Point for Kymera Therapeutics?
Add to Watchlist
Select watchlists to add or remove KYMR